Elzonris
What Elzonris is used for
Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Elzonris
- Active substance
- tagraxofusp
- Disease area
- Lymphoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX67
- Marketing authorisation holder
- Stemline Therapeutics B.V.
- Authorised in the EU since
- 2021
Official information
In the USA
Same active substance: Elzonris
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elzonris used for?
Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
What is the active substance in Elzonris?
Elzonris contains tagraxofusp.
Who makes Elzonris?
The EU marketing authorisation holder is Stemline Therapeutics B.V..
Is Elzonris an orphan medicine?
Yes. Elzonris is designated an orphan medicine in the EU, for a rare disease (Lymphoma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU